Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial

Detalhes bibliográficos
Autor(a) principal: de Araújo,Érica Maria Rodrigues
Data de Publicação: 2022
Outros Autores: Meneses,Gdayllon Cavalcante, Carioca,Antônio Augusto Ferreira, Martins,Alice Maria Costa, Daher,Elizabeth De Francesco, da Silva Junior,Geraldo Bezerra
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Jornal Brasileiro de Nefrologia
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002022005045403
Resumo: ABSTRACT Introduction: Supplementation with probiotics for patients with chronic kidney disease (CKD) may be associated with decreased systemic inflammation. Objective: To assess the impact of oral supplementation with probiotics for patients with CKD on hemodialysis. Method: This double-blind randomized clinical trial included 70 patients on hemodialysis; 32 were given oral supplementation with probiotics and 38 were in the placebo group. Blood samples were collected at the start of the study and patients were given oral supplementation with probiotics or placebo for three months. The probiotic supplement comprised four strains of encapsulated Gram-positive bacteria: Lactobacillus Plantarum A87, Lactobacillus rhamnosus, Bifidobacterium bifidum A218 and Bifidobacterium longum A101. Patients were given one capsule per day for 3 months. Blood samples were taken throughout the study to check for inflammatory biomarkers. Non-traditional biomarkers Syndecan-1, IFN-y, NGAL, and cystatin C were measured using an ELISA kit, along with biochemical parameters CRP, calcium, phosphorus, potassium, PTH, GPT, hematocrit, hemoglobin, glucose, and urea. Results: Patients given supplementation with probiotics had significant decreases in serum levels of syndecan-1 (239 ± 113 to 184 ± 106 ng/mL, p = 0.005); blood glucose levels also decreased significantly (162 ± 112 to 146 ± 74 mg/dL, p = 0.02). Conclusion: Administration of probiotics to patients with advanced CKD was associated with decreases in syndecan-1 and blood glucose levels, indicating potential improvements in metabolism and decreased systemic inflammation.
id SBN-1_e96f353f5594486e4efab7fca57ac8ff
oai_identifier_str oai:scielo:S0101-28002022005045403
network_acronym_str SBN-1
network_name_str Jornal Brasileiro de Nefrologia
repository_id_str
spelling Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trialRenal Insufficiency, ChronicProbioticsGastrointestinal MicrobiomeInflammationBiomarkersABSTRACT Introduction: Supplementation with probiotics for patients with chronic kidney disease (CKD) may be associated with decreased systemic inflammation. Objective: To assess the impact of oral supplementation with probiotics for patients with CKD on hemodialysis. Method: This double-blind randomized clinical trial included 70 patients on hemodialysis; 32 were given oral supplementation with probiotics and 38 were in the placebo group. Blood samples were collected at the start of the study and patients were given oral supplementation with probiotics or placebo for three months. The probiotic supplement comprised four strains of encapsulated Gram-positive bacteria: Lactobacillus Plantarum A87, Lactobacillus rhamnosus, Bifidobacterium bifidum A218 and Bifidobacterium longum A101. Patients were given one capsule per day for 3 months. Blood samples were taken throughout the study to check for inflammatory biomarkers. Non-traditional biomarkers Syndecan-1, IFN-y, NGAL, and cystatin C were measured using an ELISA kit, along with biochemical parameters CRP, calcium, phosphorus, potassium, PTH, GPT, hematocrit, hemoglobin, glucose, and urea. Results: Patients given supplementation with probiotics had significant decreases in serum levels of syndecan-1 (239 ± 113 to 184 ± 106 ng/mL, p = 0.005); blood glucose levels also decreased significantly (162 ± 112 to 146 ± 74 mg/dL, p = 0.02). Conclusion: Administration of probiotics to patients with advanced CKD was associated with decreases in syndecan-1 and blood glucose levels, indicating potential improvements in metabolism and decreased systemic inflammation.Sociedade Brasileira de Nefrologia2022-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002022005045403Brazilian Journal of Nephrology n.ahead 2022reponame:Jornal Brasileiro de Nefrologiainstname:Sociedade Brasileira de Nefrologia (SBN)instacron:SBN10.1590/2175-8239-jbn-2022-0021eninfo:eu-repo/semantics/openAccessde Araújo,Érica Maria RodriguesMeneses,Gdayllon CavalcanteCarioca,Antônio Augusto FerreiraMartins,Alice Maria CostaDaher,Elizabeth De Francescoda Silva Junior,Geraldo Bezerraeng2022-09-08T00:00:00Zoai:scielo:S0101-28002022005045403Revistahttp://www.bjn.org.br/ONGhttps://old.scielo.br/oai/scielo-oai.php||jbn@sbn.org.br2175-82390101-2800opendoar:2022-09-08T00:00Jornal Brasileiro de Nefrologia - Sociedade Brasileira de Nefrologia (SBN)false
dc.title.none.fl_str_mv Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial
title Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial
spellingShingle Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial
de Araújo,Érica Maria Rodrigues
Renal Insufficiency, Chronic
Probiotics
Gastrointestinal Microbiome
Inflammation
Biomarkers
title_short Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial
title_full Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial
title_fullStr Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial
title_full_unstemmed Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial
title_sort Use of probiotics in patients with chronic kidney disease on hemodialysis: a randomized clinical trial
author de Araújo,Érica Maria Rodrigues
author_facet de Araújo,Érica Maria Rodrigues
Meneses,Gdayllon Cavalcante
Carioca,Antônio Augusto Ferreira
Martins,Alice Maria Costa
Daher,Elizabeth De Francesco
da Silva Junior,Geraldo Bezerra
author_role author
author2 Meneses,Gdayllon Cavalcante
Carioca,Antônio Augusto Ferreira
Martins,Alice Maria Costa
Daher,Elizabeth De Francesco
da Silva Junior,Geraldo Bezerra
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv de Araújo,Érica Maria Rodrigues
Meneses,Gdayllon Cavalcante
Carioca,Antônio Augusto Ferreira
Martins,Alice Maria Costa
Daher,Elizabeth De Francesco
da Silva Junior,Geraldo Bezerra
dc.subject.por.fl_str_mv Renal Insufficiency, Chronic
Probiotics
Gastrointestinal Microbiome
Inflammation
Biomarkers
topic Renal Insufficiency, Chronic
Probiotics
Gastrointestinal Microbiome
Inflammation
Biomarkers
description ABSTRACT Introduction: Supplementation with probiotics for patients with chronic kidney disease (CKD) may be associated with decreased systemic inflammation. Objective: To assess the impact of oral supplementation with probiotics for patients with CKD on hemodialysis. Method: This double-blind randomized clinical trial included 70 patients on hemodialysis; 32 were given oral supplementation with probiotics and 38 were in the placebo group. Blood samples were collected at the start of the study and patients were given oral supplementation with probiotics or placebo for three months. The probiotic supplement comprised four strains of encapsulated Gram-positive bacteria: Lactobacillus Plantarum A87, Lactobacillus rhamnosus, Bifidobacterium bifidum A218 and Bifidobacterium longum A101. Patients were given one capsule per day for 3 months. Blood samples were taken throughout the study to check for inflammatory biomarkers. Non-traditional biomarkers Syndecan-1, IFN-y, NGAL, and cystatin C were measured using an ELISA kit, along with biochemical parameters CRP, calcium, phosphorus, potassium, PTH, GPT, hematocrit, hemoglobin, glucose, and urea. Results: Patients given supplementation with probiotics had significant decreases in serum levels of syndecan-1 (239 ± 113 to 184 ± 106 ng/mL, p = 0.005); blood glucose levels also decreased significantly (162 ± 112 to 146 ± 74 mg/dL, p = 0.02). Conclusion: Administration of probiotics to patients with advanced CKD was associated with decreases in syndecan-1 and blood glucose levels, indicating potential improvements in metabolism and decreased systemic inflammation.
publishDate 2022
dc.date.none.fl_str_mv 2022-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002022005045403
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0101-28002022005045403
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/2175-8239-jbn-2022-0021en
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Nefrologia
publisher.none.fl_str_mv Sociedade Brasileira de Nefrologia
dc.source.none.fl_str_mv Brazilian Journal of Nephrology n.ahead 2022
reponame:Jornal Brasileiro de Nefrologia
instname:Sociedade Brasileira de Nefrologia (SBN)
instacron:SBN
instname_str Sociedade Brasileira de Nefrologia (SBN)
instacron_str SBN
institution SBN
reponame_str Jornal Brasileiro de Nefrologia
collection Jornal Brasileiro de Nefrologia
repository.name.fl_str_mv Jornal Brasileiro de Nefrologia - Sociedade Brasileira de Nefrologia (SBN)
repository.mail.fl_str_mv ||jbn@sbn.org.br
_version_ 1752122067687309312